PeriRx is the premier developer of a breakthrough, non-invasive, oral diagnostic technology that will help healthcare professionals and their patients improve their long-term health. The company has developed a painless saliva test that uses proven bio-chemistry analytics at high sensitivity and specificity to enable early disease risk detection. This early detection of treatable diseases can enhance patient wellness while reducing the cost of healthcare.

PeriRx is introducing SaliMark™ OSCC, its first commercial saliva test for the early detection of oral squamous cell carcinoma. According to the National Institutes of Health, oral cancer is the sixth most common cancer in the world. This disease is diagnosed in over 45,000 American patients per year, and of that, over 8000 of those patients die per year – a death every hour of every single day.

PeriRx is also developing early disease detection tests based upon licensed technology from UCLA to aid in the accurate and painless diagnosis of lung cancer, Sjögren’s Syndrome, diabetes type 1 and 2, and periodontal disease.